JCM
CBIO

Jafra Capital Management’s Crescent Biopharma CBIO Stock Holding History

Jafra Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-168
Closed -$236K – 94
2017
Q3 		$236K Hold
168
– – 0.09% 71
2017
Q2 		$187K Buy
+168
New +$139K 0.07% 72

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Jafra Capital Management's CBIO Position: Q4 2017 in Review

Jafra Capital Management sold out of Crescent Biopharma (CBIO) in Q4 2017, closing a stake of 168 shares — an estimated $236K sold.

Jafra Capital Management first reported a position in CBIO in Q2 2017 and held it in 2 quarters. The position peaked at $236K in Q3 2017. 80 funds tracked by Wall St. Rank hold CBIO as of Q4 2017.

  • Jafra Capital Management reported no remaining Crescent Biopharma position as of Q4 2017 after selling out during the quarter.
  • Jafra Capital Management sold 168 Crescent Biopharma shares in Q4 2017, an estimated $236K.
  • Jafra Capital Management first reported a position in Crescent Biopharma in Q2 2017 and held it in 2 quarters.
  • Jafra Capital Management's Crescent Biopharma position peaked at $236K in Q3 2017.
  • 80 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2017.

Based on Jafra Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.